Cargando…

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound...

Descripción completa

Detalles Bibliográficos
Autores principales: Koster, Kira-Lee, Huober, Jens, Joerger, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/
https://www.ncbi.nlm.nih.gov/pubmed/36046357
http://dx.doi.org/10.37349/etat.2022.00069